Please assess the completion status of the following clinical trial:

Trial Title: A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney disease Stages 3, 4, or 5 and not receiving dialysis~* Anemia qualified by measurements of hemoglobin values during screening~* Additional blood work must be in a safe range for study entry~* Body weight 45 to 160 kilograms (kg)~* Willingness to use contraception if of child-bearing potential~Exclusion Criteria:~* Treatment with an erythropoiesis-stimulating agent (ESA) within 12 weeks prior to study participation~* More than 1 dose of intravenous iron within 12 weeks prior to study participation~* Blood transfusion within 8 weeks prior to study participation~* Active infection~* Chronic liver disease~* Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot~* Uncontrolled blood pressure within 2 weeks prior to study participation~* Renal cell carcinoma~* History of malignancy, including multiple myeloma or other myelodysplastic syndrome~* Chronic inflammatory disease that could impact red blood cell production~* Any prior organ transplant or a scheduled organ transplantation~* Anticipated elective surgery that is expected to lead to significant blood loss or anticipated elective heart procedure~* Gastrointestinal bleeding~* Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)~* Recent use of an investigational drug or treatment, or participation in an investigational study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roxadustat (Type: EXPERIMENTAL): Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing \<70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing \<70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).